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Interferon-alpha (IFN-a) is widely used for the treatment of viral infections and primary cancers. In the present
study, we investigated whether the anti-proliferative activity of IFN-a is capable of inhibiting melanoma tumor
development in the absence of protective immune responses in a severe combined immunodeﬁciency (SCID)
mouse model. Mice treated with either regular (100 lg/ 3 times per week) or pegylated (300 lg/ once weekly) human
IFN-a 2a showed a marked reduction in tumor weight after 4 wk of treatment. Tumor weight in pegylated and
conventional IFN-a-treated animals was reduced by 61% and 67%, respectively, as compared to saline control (both
pp0,01). A decrease of proliferation and an increase of apoptotic tumor cells were observed in IFN-treated tumors.
DNA microarrays were applied to analyze transcriptional responses in tumors after 4 wk of treatment and a subset
of about 90 genes was differentially expressed. Twenty-four novel and ﬁve known interferon-inducible genes were
up- and 65 genes downregulated. A direct comparison of IFN-a and pegylated IFN-a did not reveal any significant
differences in tumor growth inhibition indicating that this novel and more stable class of IFN is functionally
equivalent. Despite the structural difference between pegylated and conventional IFN-a, both agents caused similar
transcriptional responses in human melanoma xenotransplants.
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Interferons (IFN) play a key role in mediating anti-viral, anti-
tumor and immune-modulating responses. Signaling is fast
and involves tyrosine phosphorylation and downstream ac-
tivation of signaling molecules, which induce the expression
of genes with IRE’s located in the 50 promoter region. Type I
(predominantly a and b) and type II (g) interferon’s signal
through distinct pathways and specific cell surface recep-
tors, but exhibit similar biological effects particularly with
regard to their anti-proliferative activities (Stark et al, 1998;
Platanias and Fish, 1999). The anti-tumor potential of inter-
feron’s was encouraging in animals, but only limited suc-
cess was achieved in human trials using IFN-a in advanced
disease (Gutterman, 1994). In melanoma, interferon-alpha
(IFN-a) is widely used in the adjuvant setting with clear
clinical efficacy in subgroups of patients (Kirkwood et al,
1996; Grob et al, 1998; Pehamberger et al, 1998; Kirkwood
et al, 2000).
The availability of primary melanoma cell lines from IFN-a
sensitive and IFN-a resistant patients allowed to analyze the
molecular basis of IFN-a responses. IFN-a inhibited cell
proliferation in sensitive cell lines and induced HLA class I
expression, which was not the case in IFN-a-resistant cell
lines (Certa et al, 2001). DNA microarray technology has
largely extended the number of known genes responding to
IFN-a in sensitive or resistant human melanoma cell lines
and a fibrosarcoma cell line (Der et al, 1998; Certa et al,
2001).
The inhibition of proliferation in cell lines suggests that at
least one mechanism of interferon action operates in the
absence of an immune system. Indeed, the products of
some IFN-a-inducible genes have been associated with
control of proliferation, as the Leu-13 protein family, which
has anti-proliferative effects in leukocytes and endothelial
cells (Deblandre et al, 1995).
Notably, Leu-13 is not inducible in resistant melanoma
lines. Recent work in our laboratory has shown that regu-
lated expression of Leu-13 transgene is sufficient to inhibit
cell proliferation of melanoma cells (unpublished results). It
is therefore conceivable that the anti-proliferative activity
of certain IFN-a-inducible genes is sufficient to arrest cell
division during tumor development in vivo.
Human tumors including melanoma grow in severe
combined immunodeficiency (SCID) mice, which lack
functional B and T cells. In addition, it has been shown
that tumor growth can be controlled in this model by an
Abbreviations: EST, expressed sequence tag; IFN-a, interferon-
alpha; IRE, interferon response element; PEG-IFN-a, pegylated in-
terferon-alpha; SCID, severe combined immunodeficiency
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anti-sense oligonucleotide approach targeting bcl-2 (Jan-
sen et al, 1998). This experimental system, together with
the fact that interferon activity is species restricted, allows
to investigate whether IFN-a inhibits melanoma tumor de-
velopment in the absence of host immune responses. A
global DNA microarray analysis of the transcriptional re-
sponses in the tumors was included to obtain additional
insight into the underlying mechanisms of tumor develop-
ment and arrest.
Results
Tumor growth inhibition Inhibition of tumor growth of
melanoma xenotransplants, as determined by caliper meas-
urement of the tumors in week 3, was inhibited to a very
similar extent by 88% (IFN-a) and 86% (pegylated interfer-
on-alpha, PEG-IFN-a), respectively (both pp0,01), as com-
pared to the control group (Fig 1A; IFN-a 0.053  0.038,
PEG-IFN-a 0.06  0.065, saline buffer (SAL) 0.44  0.17).
After 4 wk of treatment, mice were euthanized.
Difference in tumor weight In IFN-a-treated animals
tumor weight was reduced by 67% and in PEG-IFN-a-
treated animals by 61%, respectively (both pp0.01), as
compared to the control group (Fig 1B; IFN-a 0.3  0.15;
PEG-IFN-a 0.26  0.18; SAL 0.8  0.18).
Species speciﬁcity of IFN-a No difference was observed in
the mouse weights of all groups (Fig 1B) and both treatments
were well tolerated with no apparent sign of toxicity. Spleens
were weighted and found to be similar in all groups (Fig 1B).
As a further control, we extracted RNA from the isolated
spleens and performed transcript imaging using commercial
oligonucleotide arrays (U74A, Affymetrix, Santa Clara, Cal-
ifornia). This molecular analysis showed no differences
between the control and experimental animals and the ex-
pression of only about 50 of 11,400 genes was modulated
greater than 1-fold in each group and not a single gene
showed a change factor greater than 3-fold (data not shown).
None of the upregulated genes belonged to the class of
known IFN-inducible genes confirming absent stimulatory or
inhibitory effects of IFN-a in mouse spleen cells.
Reduction of cell proliferation We performed Ki67 stain-
ing on tumor tissue samples of PEG-IFN-a and saline-treat-
ed animals and were able to detect a marked decrease in
proliferation in the PEG-treated tumors as opposed to the
controls after 4 wk of treatment (Fig 2A, B).
Induction of apoptosis We performed TdT-mediated
dUTPnick end labeling (TUNEL) apoptosis detection assays
on tumor tissue samples. After 4 wk of treatment with PEG-
IFN-a, we found a marked increase in the number of apo-
ptotic cells in PEG-IFN-a as opposed to saline-treated an-
imals (Fig 2C, D).
Gene expression analysis We next analyzed the global
changes in gene expression in the tumors. About 40% of
transcripts were detected (average difference 440; pp
0.05) in all groups of mice independent of the treatment.
Indeed, a common set of only 90 genes was differentially
expressed in the treated mice compared to the control
group. Thirty genes were induced and 60 downregulated
more than 2-fold (Fig 3) and these numbers did not change
significantly when the stringency parameters for gene
selection were lowered (data not shown).
Only five (MxB, leu-13, Kip1, Rig-E, BST-2; see Table I,
solid box) of the induced genes belong to the family of ap-
proximately 100 known IFN-a-inducible genes with interfer-
on response elements (IRE) in the 50 regulatory region. Of
these, three encode proteins involved in cell proliferation or
cell growth.
The Leu-13 antigen inhibits cell proliferation based on
antibody-inhibition experiments or recent functional studies
in our laboratory using a genetic approach (Deblandre et al,
1995). Conversely, the gene is silenced after tumorigenic
transformation of mouse mast cells that develop into tumors
when implanted into mice (Brem et al, 2001).
Kip-1 or p27 controls cell cycle progression and under-
goes a similar regulation in tumorigenesis. In hepatocellular
carcinoma cells the augmentation of anti-tumor activity of
5-fluorouracil by IFN is associated with upregulation of
KIP-1, which causes arrest of cell cycle progression (Eguchi
et al, 2000).
RIG-E: All-trans-retinoic acid (ATRA) causes clinical re-
mission in patients with acute promyelotic leukemia. This
Figure 1
Human melanoma SCID mouse xenotransplantation model. (A) Tumor growth curves and treatment schedules of mice treated with 900 mg PEG-
IFN-a (300 mg IFN-a equivalent) once weekly (PEG,’), 100 mg IFN-a three times per week (IFN, m) or saline buffer (SAL,E). Squares indicate the
time points when PEG-IFN-a or IFN-a were injected. (B) Tumor, spleen, and mouse weight after 4 wk of treatment.
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results in expression of common retinoic acid-inducible
transcription factors including the IFN-inducible gene RIG-
E, which is the human homologue of murine Ly6, a signal
transduction molecule involved in cell differentiation and
growth (Mao et al, 1996).
MxB, also termed cellular resistance protein, is involved
in the inhibition of viral replication. Like Leu-13, the p78
gene is not IFN inducible in a resistant human melanoma
cell line as compared to a sensitive line (U. Certa, unpub-
lished results).
Bst-2 is a cell surface antigen on multiple myeloma cells
and a target of antibody-based immunotherapy that induc-
es cell lysis by antibody-dependent cell-mediated cytotox-
icity (ADCC). The role of Bst-2 in tumorigenesis, however, is
unclear.
XAF1 (XIAP associated factor 1) is one of the other up-
regulated genes. It has been described recently by Leaman
et al (2002) to be type I IFN inducible and to augment TNF
related apoptosis-inducing ligand (TRAIL)-induced apoptosis
in melanoma cell lines in vitro. It is an antagonist of the anti-
apoptotic factor XIAP (Sparwasser et al, 1998; Liston et al,
2001) and could therefore function as a tumor suppressor.
Another interesting upregulated gene is AGOUTI that
encodes the ASP, the human homologue of the murine
agouti protein involved in pigmentation patterning. The
agouti protein inhibits B16 melanoma cell development
in vitro (Siegrist et al, 1996) and it might therefore contribute
to the inhibition of tumor development in our study. The IFN-
inducible protein Viperin (cig5) prevents productive human
cytomegalovirus (HCMV) infection in fibroblasts (Chin and
Cresswell, 2001) a process in which cells show a marked
reduction in proliferation.
The remaining known genes upregulated in the tumor
samples include the cell adhesion molecule B-cam and five
cell surface receptors and seven expressed sequence tags
(EST) (see Table I).
Additional functional studies will be needed in order to
elucidate the association of the remaining genes including
EST with tumor development, because they are candidates
for novel tumor suppressor genes. Based on database
searches, a number of these genes lack classical IRE el-
ements in their 50 promoter regions and it is unclear at this
point how they are induced (data not shown).
The set of repressed genes in our experiment (Table I) is
equally important because it may contain novel oncogenes
or genes involved in tumor growth and promotion. Interest-
ingly VEGF, normally involved in angiogenesis that repre-
sents an essential process during metastasis, was sig-
nificantly decreased indicating a possible IFN-dependent
anti-tumor effect. Further morphometric analysis of the vas-
cularity in melanoma xenografts is needed to proof this
assumption. Another gene found to be repressed is MGSA
(melanoma growth stimulatory activity, CXCL1), which is
expressed in the majority of melanoma lesions and probably
involved in tumorigenesis (Luan et al, 1997; Dhawan and
Richmond, 2002). The group of downregulated genes in-
cludes also 15 EST and interestingly a cluster of seven
Figure3
Cluster analysis of the genes involved in tumor growth inhibition.
Genes were selected based on change factors and low experimental
variation and details appear in Table I. Shades of red indicate grades of
up- and of blue downregulation. Expression values in the saline-treated
group were used as baseline. The HSP-70 gene, the only gene induced
by PEG-IFN-a (PEG) and suppressed by IFN-a (IFN) is highlighted with
a hatched box marked by an arrow.
Figure 2
Immunohistological analysis of human melanoma xenotransplants Ki67
proliferation assay of tumors (A, B), apoptosis in tumor biopsies as-
sessed by TUNEL staining (C, D), saline (A, C), and PEG treated (B, D),
after 4 wk of treatment, scale bars¼ 250 mm (A, B) and 500 mm (C, D).
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genes involved in the control of phosphorylation and signa-
ling (Table I, hatched box).
Discussion
Our data show that both PEG-IFN-a once weekly and con-
ventional IFN-a three times per week inhibit melanoma
growth significantly as compared to a control group. Tumor
growth in both groups was reduced to a similar extent. This
suggests that PEG-IFN-a will be equally efficient in therapy
as conventional IFN-a with the benefit of fewer injections,
which would result in considerable savings for hospitals and
public health systems. Moreover, the significant arrest of
tumor development seen in the animal model suggests that
high doses of IFN might inhibit the growth of metastasizing
Table I. List of differentially regulated genes in IFN-a and PEG-IFN-a-treated tumors with saline-treated tumors as baseline
DB ID Description PEG CHF IFN CHF DB ID Description PEG CHF INF CHF
M30818 p78 (MxB) 5.75 2.04 D84110 RBP-MS 2.87 4.2
J04164 9–27 (leu-13 protein) 2.05 2.14 X68742 Integrin, a subunit 4.91 3.43
X67325 p27 (Kip1) 2.27 1.84 AF032906 Cathepsin Z precursor 4.21 4.16
U66711 Ly6 (Rig-E) 1.87 2.45 D50683 TGF-b a 2.11 6.84
D28137 BST-2 1.48 0.99 X51757 HSP70B 2.55 12.3
AF026941 cig5 58.1 5.7 X69549 GDP-dissociation Inhibitor 2 4.68 5.25
X80026 B-cam 7.65 33.8 X54489 MGSA (melanoma) 2.64 8.02
AF062006 GPCRHG38 27.38 9.3 D38037 FKBP-12 2.72 8.48
X66403 Acetylcholine receptor-e 11.05 24.7 U63717 Osteoclast stimulating factor 3.56 9.24
X99699 XIAP associated factor-1 17.85 6.75 AL021155 Brain natriuretic protein 8.18 5.02
M14199 Laminin receptor (2H5 epitope) 5.5 15.54 AB012853 ING1L 2.3 11.28
M17886 Ribosomal phosphoprotein P1 6.29 11.06 Z50194 PQ-rich protein 2.56 15.9
X00457 SB classII antigen a-chain 5.9 10.19 X14813 3-oxoacyl-CoA thiolase 16.25 3.73
L13740 TR3 orphan receptor 12.25 3.58 J05459 GSTM3 16.85 4.41
D87002 Immunoglobin light chain 4.14 6.91 AF042273 STAM2 2.83 23.9
U12775 AGOUTI protein 5.11 5.3 AF039029 Snurportin1 14.75 14.75
AJ005890 JM1 2.18 7.73 U24578 C4B precursor 15 15
U89337 HLA class III region 3.81 3.97 L42450 PDK1 9.47 26.75
U20582 Actin-lile peptide 3.33 3.59 L76927 Galactokinase 20 20
S37730 IGF-BP 2 3.41 3.31 AL031983 Diubiquitin 33.85 7.2
L39064 Interleukin 9 receptor precursor 2.82 2.78 X90857 14 gene 6.22 49.15
X80907 p85 subunit of PI-3-kinase 3.52 3.16 D43968 AML1b 51 20.22
þ Seven EST’s up up X71129 Electron transfer flavoprotein 96.25 5.78
U31384 G protein g-11 2.14 2.26 M63978 VEGF 15.45 9.97
M33195 Fc-e-receptor 2.41 2.2 L27560 IGF binding protein 4.35 2.44
U49957 LIM protein 2.6 2.06 S62539 Insulin receptor substrate-1 2.92 3.16
AL035079 Catalase 2.59 2.31 U34994 DNA-dependent protein kinase 2.25 3.87
D87258 Serin protease 3.09 2.24 J02923 65-kDa phosphoprotein 2.75 3.43
U66061 Trypsinogen C 2.71 2.63 M65254 Protein phosphatase 2A 4.29 2.73
S69189 Acyl-coenzyme A oxidase 2.33 3.68 M68516 Protein kinase C inhibitor 2.47 2.36
J00140 DHFR 3.09 3.13 X95632 Tyrosine kinase-binding protein 4.75 16.25
X71345 Trypsinogen IV b-form 2.12 4.38 AF051160 PRL-1 tyrosine phosphatase 4.86 40.6
Y08110 Mosaic protein LR11 3.2 3.49 X68277 CL 100 tyrosine phosphatase 6.27 45.5
U95735 YKT6 3.15 100.6 þ Fifteen EST Down Down
The genes were selected based on a change factor (CHF) greater than 2-fold and a p-value smaller than 0.05. The genes with gray shaded accession
numbers are induced and the unmarked downregulated. Known IFN-a-inducible genes are marked with a solid box and the cluster of downregulated
genes involved in signaling is highlighted with a hatched box. Genes referred to in the text are in bold script. The EST in each category are summarized
without further details.PEG-IFN-a, pegylated interferon-alpha; EST, expressed sequence tags.
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tumors provided that new IFN formulations overcome
tolerance and side effects. Once this is achieved the
widespread phenomenon of IFN-a resistance remains to
be solved and the approach presented here might be suited
to understand the molecular basis of resistance.
Due to the species specificity of IFN-a, the use of human
IFN-a in a xenotransplantation model allows the study of
direct IFN effects on the tumor cells, excluding any other
possible mechanisms, e.g., via immune stimulation. In ac-
cordance with this we observed no toxicity in any animals.
In addition, gene expression analysis of the mouse spleen
cells showed no difference between treated and control
animals, indicating the expected absence of immune stim-
ulation by human IFN-a in the treated mice. To gain further
insight into the mechanisms of direct tumor growth inhibi-
tion in our model, we performed proliferation and apoptosis
assays on tissue samples (Fig 2). These showed a marked
decrease cell proliferation as well as an increase in apo-
ptotic tumor cells in the IFN-treated animals. The anti-pro-
liferative effect is in accordance with previous data (Certa
et al, 2001) showing anti-proliferative activity of IFN-a
in vitro and is supported by the observed differences in gene
expression. The observed induction of apoptosis points to-
ward a role of apoptosis in the mediation of growth control
in our model and may confirm the observed upregulation of
XAF-1, a pro-apoptotic factor, in IFN-treated tumors.
We reported earlier that in vitro IFN-a stimulation of sen-
sitive human melanoma cells results in the upregulation of
about 100 genes without the repression of a single gene
(Certa et al, 2001). A similar picture emerges from the tran-
script analysis of interferon-a-, -b-, and -g-treated human
fibrosarcoma cell lines (Der et al, 1998). It is thus reasonable
to propose that the observed major gene downregulation
associated with tumor growth control is a secondary rather
than a direct effect of IFN signaling through the classical
JAK/STAT pathway(Certa et al, 2003). The observed down-
regulation of seven genes encoding signaling molecules is
consistent with this view (Table I, hatched box). We are
aware that the transcriptional analysis of xenotransplanted
tumors of multiple cell lines would strengthen the gene ex-
pression data by determining whether the observed regu-
lations are specific to the 518A2 human melanoma cell line.
The clear-cut gene expression alterations found in a single
cell line, however, strongly indicate significant IFN effects.
Our data show that conventional INF-a and PEG-IFN-a
elicit the same functional and transcriptional responses.
This is surprising because PEG-IFN-a is considerably larger
due to the attachment of polyethylene glycol moieties,
which could impair receptor binding or affinity. Only a single
gene (heat shock protein HSP-70; highlighted in Fig 2), out
of the 12,000 analyzed, was suppressed by IFN-a and in-
duced by PEG-IFN-a. The microarray technology applied is
therefore a sensitive tool to compare the efficacy of drug
variants with a common biological target in cellular assays
and ultimately in clinical trial monitoring.
Materials and Methods
In vivo studies Pathogen-free female SCID mice were obtained
from Harlan–Winkelmann (Borchen, Germany). Animals were
housed in microisolator cages in laminar flow racks and received
autoclaved food and water ad libitum. 518A2 human melanoma
cells were maintained in basal tissue culture medium (DMEM,
Gibco BRL, Paisley, Scotland) supplemented with 10% fetal calf
serum (FCS) and 1% antibiotics in a humidified 5% CO2, 95%
ambient air atmosphere at 371C. 18 SCID mice were injected sub-
cutaneously (s.c.) into the left lower flank with 1.5  107 518A2
human melanoma cells resuspended in 200 mL phosphate-buffered
saline (PBS). Subsequently, animals were randomized into three
treatment groups of n¼ 6 and s.c. treatment into the opposite flank
of the tumor was started on the same day.
The first group was treated with 900 mg PEG-IFN-a (F. Hoff-
mann-La Roche, Basel, Switzerland) (300 mg IFN-a equivalent)
once weekly. In PEG-IFN-a 2a, a branched polyethylene glycol
molecule is chemically coupled to lysine residues of INF-a 2a,
which results in improved serum stability (Motzer et al, 2001). The
second group was treated with 100 mg IFN-a (F. Hoffmann-La
Roche) three times per week and a control group received saline
solution. Dosages of IFN-a and PEG-IFN-a were adapted accord-
ing to previous renal cell carcinoma experiments in nude mice
(Pegasys Investigational Drug Brochure, F. Hoffmann-La Roche,
unpublished results). Tumor size was assessed weekly by caliper
measurement. After 4 wk of treatment, mice were euthanized and
tumor weight, spleen weight, and mouse weight were evaluated.
Tumors and spleens were snap frozen in liquid nitrogen and stored
at 801C.
The experiment was repeated as above with PEG-IFN-a and a
control group. Mice were sacrificed after 4 wk of treatment and
tumors conserved for histological analysis.
The study was approved by the University of Vienna Animal
Welfare Committee.
Statistical analyses Statistical significance of differences in
tumor weight among treatment groups was calculated by using
the Mann–WhitneyU test (Statistica 5.1, StatSoft, Tulsa, Oklaho-
ma). p-values o0.05 were considered to be of statistical signifi-
cance.
Ki67 staining Paraffin sections (5 mm) of tumor tissue were de-
waxed and subjected to endogenous peroxidase block for 15 min.
Then the slides were boiled three times for 5 min each in 1 
citrate buffer at 700 W in the microwave. After cooling for 30 min
the slides were washed twice using Tris-buffer (pH 7.4) and incu-
bated overnight at 41C with primary Ki-67 antibody (Dianova,
Hamburg, Germany, clone MIB-1) diluted 1:50 in blocking solution
(Superblock #37515, Pierce, Rockford, Illinois). Following washing
with Tris-buffer twice for 5 min, slides were incubated for 30 min
with secondary biotinylated anti-mouse antibody (LSAB Kit, DAKO,
Glostrup, Denmark). After washing twice with Tris-buffer, sections
were incubated with horseradish peroxidase (LSAB Kit, DAKO) for
30 min. Antibody binding was visualized by further incubation with
DAB Substrate Kit (DAKO) for 3 min. After further washing with Tris-
buffer, slides were counterstained with Haemalaun (Merck, Haar,
Germany), and covered in Aquatex (Merck).
TUNEL TUNEL immunohistochemistry was performed in tumor
xenotransplants embedded in paraffin according to the manufac-
turer’s protocol (Roche Diagnostics, Mannheim, Germany). In brief,
tissue sections were dewaxed and incubated for 1 h in a humidified
chamber at 371C with proteinase K. PBS rinsed slides were then
covered with the TUNEL reaction mixture and incubated again for
one h in a humidified chamber at 371C. Control sections were
incubated with nucleotide mixture alone. Sections were then coun-
terstained with DAPI nuclear stain and apoptotic index was deter-
mined by fluorescence microscopy. Only comparable sections of
the outer layers of the tumor without signs of necrotic areas or
physically damaged cell morphology in H&E (hematoxyline and
eosin) staining were analyzed.
Microarray analysis RNA extraction was performed on tumor tis-
sue samples from all animals. Equivalent amounts of RNA were
processed and labeled for microarray analysis (Certa et al, 2001)
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using commercial human U95A arrays (Affymetrix) where a given
transcript is represented by 16 pairs of synthetic 22-mer oligonuc-
leotides, which are synthesized in distinct 20 mm features using
photolithography. One such probe set has the authentic sequence
(perfect match; PM), whereas a control set is synthesized with a
single mismatch (MM) in the center position to monitor unspecific
and background hybridization. The transcripts abundance of a
given gene is expressed as the average difference (AD) between
the PM and MM probe sets.
Visual inspection of the total RNA samples before processing
by agarose gel electrophoresis did not reveal any signs of degra-
dation or yield in the tumor samples. The number of replicates in
each group (n¼ 6) allows the application of statistical algorithms
for data analysis in order to account for experimental variation. An
average difference of42 and pp0.05 were considered significant.
Data analysis was performed as described by Brem et al (2001).
Probe arrays were scanned with a GeneChip Scanner (Affymetrix
Inc). Pixel intensities were measured, and expression signals were
analyzed with commercial software (GeneChip Analysis Software,
Affymetrix). Detailed data analysis were carried out by using RACE-
A (F. Hoffmann-La Roche) and EXEL (Microsoft, Redmond,
Washington) software.
Microarray analysis of mouse spleen cells was performed in a
similar fashion using commercial murine U74A arrays (Affymetrix).
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